Recommending Exercise for Migraine: Just Do It

Strength training is the most effective form of exercise for reducing migraine, with high-intensity aerobics coming in second, and both beating top-line migraine medications topiramate and amitriptyline, new research suggests. The new results should encourage clinicians to recommend patients with migraine engage in strength-training exercise whenever possible, study author Yohannes W. Woldeamanuel, MD, a physician-scientist … Read more

Single Dose of Psilocybin for Major Depression Tied to Short-Term Remission

A single 25 mg dose of synthetic psilocybin in combination with psychotherapy appears to effectively ease symptoms of treatment-resistant depression (TRD) — at least in the short-term, new research shows. In the largest study of psilocybin for TRD to-date, results of the phase 2b randomized, double-blind trial show participants in the 25-mg dose group experienced … Read more

ECT Tops Ketamine for Major Depression

Electroconvulsive therapy (ECT) is more effective than intravenous (IV) ketamine for patients experiencing a major depressive episode (MDE) in new findings that are in line with the KetECT study ― the first head-to-head trial of ketamine and ECT. As reported by Medscape Medical News, the KetECT trial was published earlier this year. It showed that … Read more

Home-Based Transcranial Stimulation Succeeds for Major Depression

Home-based transcranial direct current stimulation with real-time supervision significantly improved clinical symptoms of major depressive disorder, based on data from 26 individuals. Major depressive disorder (MDD) remains a leading cause of disability and a significant predictor of suicide worldwide, Rachel D. Woodham, PhD, of the University of East London and colleagues wrote. Transcranial direct current … Read more

Stress Key to Link Between Computer Vision Syndrome and Migraine

Computer vision syndrome (CVS), a condition involving eye problems resulting from screen time with digital devices, is significantly associated with both insomnia and migraine — with stress as a central mediating factor, new research suggests. Investigators administered an online questionnaire to more than 700 adults, of whom 71% had CVS. Results showed the presence of … Read more

No Evidence Low Serotonin Causes Depression?

There is no convincing evidence that low serotonin levels are the primary cause of depression. This is the conclusion of an “exhaustive” review by UK investigators, which upends the widely held belief that depression is the result of lower levels, or reduced activity, of the chemical. Researchers say the results call antidepressant use into question. … Read more

CBT May Improve Comorbid Posttraumatic Headache, PTSD

Cognitive-behavioral therapies (CBTs) can provide relief from comorbid, persistent posttraumatic headache and posttraumatic stress disorder (PTSD), new research suggests. Results from a randomized clinical trial of almost 200 military veterans showed that, compared with usual care, CBT for headache led to significant improvement in both headache disability and PTSD symptoms. Cognitive processing therapy (CPT) also … Read more

Triptans in Pregnancy and ADHD in Kids: New Reassuring Data

Triptan use during pregnancy does not increase the risk for attention-deficit/hyperactivity disorder (ADHD) in offspring, new research suggests. Hedvig Nordeng, PhD “The findings should satisfy women who need to take this class of drugs during pregnancy,” study author Hedvig Nordeng, PhD, professor and head of the Pharmacoepidemiology and Drug Safety Research Group at the University … Read more

Two Promising Bridge Therapies for Medication Overuse Headaches

This study was published as a preprint and has not yet been peer reviewed. Key Takeaway Among patients with MOH of longer duration, response to treatment was lower, highlighting the importance of early diagnosis and rapid treatment for these headaches. Why This Matters MOH affects 1% to 2% of the general population. It is a … Read more

Psilocybin Effective Up to 12 Weeks in Severe Depression

NEW ORLEANS – A single dose of a synthetic formulation of psilocybin provides rapid improvement in treatment-resistant depression, with benefits sustained for up to 12 weeks, according to results from the largest randomized controlled study of psilocybin to date. Dr Guy Goodwin “This is easily the largest study of a psychedelic drug employing modern randomized … Read more